Malaria DNA vaccine - University of Oxford

Drug Profile

Malaria DNA vaccine - University of Oxford

Latest Information Update: 09 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Oxford
  • Developer Oxxon Therapeutics; Pfizer; University of Oxford
  • Class Antimalarials; DNA vaccines; Gene therapies; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 16 Dec 2003 A phase IIb trial has been completed for Malaria in Gambia
  • 09 Dec 2003 A clinical study has been added to the Parasitic Infections immunogenicity section
  • 03 Dec 2003 Phase-II clinical trials in Malaria in Gambia (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top